PARP Inhibitor Combination Shows Activity in Small Cell Lung Cancer - Cancer Therapy Advisor

PARP Inhibitor Combination Shows Activity in Small Cell Lung Cancer  Cancer Therapy Advisor

Olaparib plus temozolomide appeared safe and active in relapsed small cell lung cancer, according to the results of a single-arm phase 1/2 trial.



Comments

Popular posts from this blog

Stage 4 Lung Cancer Life Expectancy

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Free biotech stocks directory, pharma stocks, telemedicine stocks ...